Therapeutic Proteins And Oral Vaccines Market, By Drug Class (Therapeutic Proteins (Growth Factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Coagulation Factors, Others), Oral Vaccines (Live Attenuated Vaccine, Inactivated Vaccine, Recombinant Va

Therapeutic Proteins And Oral Vaccines Market, By Drug Class (Therapeutic Proteins (Growth Factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Coagulation Factors, Others), Oral Vaccines (Live Attenuated Vaccine, Inactivated Vaccine, Recombinant Vaccine, Others)), By Application (Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Therapeutic Proteins And Oral Vaccines Market, By Drug Class (Therapeutic Proteins (Growth Factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Coagulation Factors, Others), Oral Vaccines (Live Attenuated Vaccine, Inactivated Vaccine, Recombinant Vaccine, Others)), By Application (Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Therapeutic proteins are one of the prime options for biologicals as per their clinical uses. Proteins are organic compounds with a higher molecular weight. This have therapeutic effects against various diseases like cancer, Acquired immunodeficiency syndrome (AIDS), and various infectious diseases. When protein is used for therapeutic purposes, it is known as a therapeutic protein. Therapeutic proteins are proteins that are engineered in the laboratory for pharmaceutical purposes in the making of insulin to treat diabetes. Therapeutic proteins are highly effective in vivo and have revolutionized the treatment of diseases. Oral immunization is considered the most convenient route of vaccination rather than any other route due to its abundance of facilities over the traditional vaccines. Gaining of mucosal immunity through oral vaccination can act as a protector against human-to-human or animal-to-human pathogenic transmission of diseases and also inhibit the pathogenic replication in the mucosal area which is the most preferable able route of microbe’s penetration to the host blood circulation.

Market Dynamics

The key players in the therapeutic proteins and oral vaccines market are focusing on the development of vaccines, products, and research and development by market players. Thus, the introduction of such advanced products into the market is expected to drive growth of the global therapeutic proteins and oral vaccines market over the forecast period. For instance, in September 2022, Vaxart, Inc., a clinical-stage biotechnology company, reported positive top-line data from the first part of a planned two-part Phase II study of its Wuhan S-only oral pill COVID-19 vaccine candidate, VXA-CoV2-1.1-S. The data demonstrate that the trial met its primary safety and secondary immunogenicity endpoints and will inform the ongoing development of new Omicron-based vaccine constructs.

Key features of the study:

• This report provides an in-depth analysis of the global therapeutic proteins and oral vaccines market and provides market size (US$ Mn and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global global therapeutic proteins and oral vaccines market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Abbott Laboratories, Amgen, Inc., Biogen, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson and Johnson, Merck & Co.Inc., Novo Nordisk A/S, Pfizer, Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Emergent Biosolutions Inc., TransAlgae, MigVax Ltd., and Lumen Bioscience, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global therapeutic proteins and oral vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global therapeutic proteins and oral vaccines market

Therapeutic Proteins And Oral Vaccines Market Detailed Segmentation:

• By Drug Class:
• Therapeutic Proteins

Growth Factors

Fusion Proteins

Monoclonal Antibodies

Hormones

Coagulation Factors

Others

• Oral Vaccines

Live Attenuated Vaccine

Inactivated Vaccine

Recombinant Vaccine

Others

• By Application:
• Oncology
• Hematology
• Immunology
• Endocrinology
• Infectious Disease
• Cardiovascular Disease
• Others
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• Company Profiles
• Abbott Laboratories
• Amgen, Inc.
• Biogen, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Johnson and Johnson
• Merck & Co.Inc.
• Novo Nordisk A/S
• Pfizer, Inc.
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd.
• Emergent Biosolutions Inc.
• TransAlgae
• MigVax Ltd.
• Lumen Bioscience, Inc.